| Not Yet Recruiting | Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revasc NCT07426107 | Xiao Hui Zhang | — |
| Not Yet Recruiting | Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura NCT07310342 | University Hospital, Bordeaux | N/A |
| Recruiting | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thro NCT07194850 | argenx | Phase 2 / Phase 3 |
| Not Yet Recruiting | Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment NCT07059910 | Assiut University | — |
| Completed | Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq NCT07150286 | Al-Mustansiriyah University | N/A |
| Completed | Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets a NCT06444477 | University Hospital, Bordeaux | — |
| Unknown | Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University H NCT05835050 | Sohag University | N/A |
| Unknown | " Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic P NCT05585944 | Sohag University | N/A |
| Completed | A Study of PN20 in Healthy Adult Volunteers NCT06523088 | Chongqing Peg-Bio Biopharm Co., Ltd. | Phase 1 |
| Unknown | Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura NCT05093257 | Sohag University | — |
| Recruiting | Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura NCT04323748 | New York Medical College | Phase 1 |
| Unknown | H. Pylori Eradication for Moderate ITP NCT03177629 | Seoul National University Hospital | Phase 3 |
| Completed | Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia. NCT04057703 | University Hospital, Bordeaux | — |
| Withdrawn | MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in S NCT01609452 | Anthera Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Pur NCT02076412 | Rigel Pharmaceuticals | Phase 3 |
| Completed | Study to Evaluate Safety and Efficacy in Adult Subjects With ITP NCT02273960 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) NCT02077192 | Rigel Pharmaceuticals | Phase 3 |
| Completed | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura NCT02076399 | Rigel Pharmaceuticals | Phase 3 |
| Completed | Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home NCT02085993 | Amgen | — |
| Completed | A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients NCT01621204 | McMaster University | Phase 3 |
| Completed | Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia NCT01719692 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Completed | Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT NCT01652599 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Completed | Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura NCT04056507 | University Hospital, Bordeaux | — |
| Completed | Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pIT NCT01510873 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia NCT01672151 | First Affiliated Hospital of Suzhou Medical College | — |
| Completed | A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) NCT01390649 | CSL Behring | Phase 4 |
| Completed | Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura. NCT04070599 | University Hospital, Bordeaux | Phase 3 |
| Completed | Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytope NCT01668615 | First Affiliated Hospital of Suzhou Medical College | — |
| Completed | Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romi NCT01439321 | GlaxoSmithKline | — |
| Unknown | Helicobacter Pylori Immune Thrombocytopenic Purpura NCT01255332 | Cooperative Study Group A for Hematology | — |
| Completed | Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP NCT01107951 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Terminated | Initial Treatment of Patients With Immune Thrombocytopenic Purpura NCT00991939 | Carelon Research | Phase 3 |
| Completed | Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients NCT01730352 | Federal University of São Paulo | Phase 2 / Phase 3 |
| Completed | Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP NCT00718692 | Symphogen A/S | Phase 2 |
| Completed | Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatm NCT00621894 | GlaxoSmithKline | Phase 2 |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Ad NCT00426270 | Octapharma | Phase 3 |
| Completed | A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. NCT00376077 | The Hospital for Sick Children | Phase 3 |
| Completed | Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10 NCT00168038 | CSL Behring | Phase 3 |
| Completed | Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura NCT01713855 | Neufeld, Ellis J, MD, PhD | N/A |
| Completed | Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in NCT00774202 | Weill Medical College of Cornell University | Phase 2 / Phase 3 |
| Completed | An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between NCT00005570 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| No Longer Available | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP NCT03363334 | Rigel Pharmaceuticals | — |